Organon Earnings Decline Amid Pending Sun Pharma Merger
Adjusted net income fell to $230 million for the quarter ended June 30, 2026.
Organon (OGN), the women's health company, reported a decline in quarterly profitability as it awaits a merger with Sun Pharmaceutical Industries Limited.
The results follow a period of strategic transition. The company is currently in the process of an all-cash merger into Sun Pharma valued at $14.00 per share, representing an enterprise value of $11.75 billion.
Adjusted net income for the quarter ended June 30, 2026, was $230 million, down from $261 million in the same period last year. GAAP reported net income also fell to $108 million from $145 million in the prior-year quarter.
Non-GAAP adjusted diluted EPS was $0.85, a decrease from $1.00 in the prior-year quarter. The figure rose from $0.71 reported in the first quarter of 2026.
Margins contracted during the period. Adjusted non-GAAP gross margin declined to 58.7% from 61.7% a year earlier. Adjusted EBITDA margin was 29.6%, down from 32.7% in the prior-year quarter, though it rose slightly from 28.4% in the first quarter of 2026.
Financial results were impacted by the January 2026 sale of the Jada system to Laborie. The divestiture resulted in an $81 million adjustment to adjusted net income for the first six months of 2026.
Organon ceased providing financial guidance and hosting quarterly earnings calls starting in the first quarter of 2026 due to the pending merger.